Clinical trials: Tolerability
Premature Ejaculation
FTIH Study With GSK958108
This study is the first administration of GSK958108 to man. The study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK958108 and evaluate the effect of food on GSK958108 pharmacokinetics
- Trial name
- NCT00664365
- Testing
- GSK958108
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
This study is being conducted to evaluate the safety and tolerability of ascending multiple oral doses of SCA-136 adminstered to healthy Japanese and non-Japanese female subjects.
- Trial name
- NCT00458107
- Testing
- SCA-136
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Safety, Tolerability
Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study
The goal of this clinical trial is to learn if a novel strain of heat-killed Mycolicibacterium that is being considered by the International Code of Nomenclature of Prokaryotes (ICNP) as candidate species and type strain…
- Trial name
- NCT07660107
- Testing
- Heat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Kioga Inc.
Healthy Volunteer
A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers
This randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetics of RO5024048. Japanese and Caucasian healthy volunteers will be randomized to receive either single oral doses of…
- Trial name
- NCT01152671
- Testing
- RO5024048
- Where
- 2 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
COVID-19
Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
- Trial name
- NCT04479644
- Testing
- BRII-198
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Encephalitis, Japanese Encephalitis
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.
- Trial name
- NCT00314132
- Testing
- ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline
- Where
- 22 sites in United States, Australia
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy female subjects of non-childbearing potential.
- Trial name
- NCT05440799
- Testing
- BI 1819479
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV-1, HIV Infections
A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
This three stage study will evaluate the safety and tolerability of MRKAd5 HIV-1 Gag Vaccine. In Stage I subjects will be randomized to receive the vaccine at 1x10^9 viral particles/dose (vp/d) or placebo.
- Trial name
- NCT00849732
- Testing
- V520, Comparator: V520 (1x10^9 vp/d), Comparator: V520 (1x10^10 vp/d)
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neurodevelopmental Disorders
IAMA-6 Oral Dose Study in Healthy Adults
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of IAMA-6 administered orally to healthy adults.
- Trial name
- NCT06300398
- Testing
- IAMA-6
- Where
- Italy
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Iama Therapeutics S.r.l.
Type 2 Diabetes Mellitus
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00404963
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.
This study is designed to observe the safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 for a duration of 14 days, in healthy adult and healthy elderly.
- Trial name
- NCT01169714
- Testing
- 0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Kidney Disease
Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment
Researchers are looking for a better way to treat people with chronic kidney diseases. Before a treatment can be approved for patients to take, researchers do clinical studies to better understand its safety and what happens to…
- Trial name
- NCT04820621
- Testing
- Runcaciguat (BAY1101042)
- Where
- Germany
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bayer
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) doses of QLM3003 compared to placebo. Also, pharmacokinetics (PK) of qlm3003 will be evaluated.
- Trial name
- NCT05932888
- Testing
- QLM3003
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy Volunteers
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops
The objective of this study is to investigate the pharmacokinetics, safety and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (FDC) to those of preservative-free tafluprost…
- Trial name
- NCT01434888
- Testing
- Preservative free tafluprost 0.0015% eye drops, Preservative free timolol 0.5% eye drops, Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Santen Oy
Healthy
A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body
The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.
- Trial name
- NCT05633862
- Testing
- BI 1015550
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pharmacokinetics
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.
The purpose of this study is to determine how well tolerated and safe AZD8566 is when given over 10 days, at different dose levels.
- Trial name
- NCT00844103
- Testing
- AZD8566
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
AD - Alzheimer's Disease, MCI
A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called [18F]Flortaucipir Injection, which is…
- Trial name
- NCT07580703
- Testing
- [18F]Flortaucipir Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Radiopharma
Skin Smoothness, Radiance
Clinical Case Study Evaluating the Efficacy and Tolerability of a Topical Facial Treatment on Healthy Females with Fitzpatrick Skin Types V and VI
This single-center, open-label, clinical case trial was conducted to evaluate the efficacy and tolerability of a topical facial treatment when applied by a license esthetician in clinic in a series of 3 sessions with 1 month…
- Conditions
- Skin Smoothness, Radiance, Overall Appearance
- Trial name
- NCT06633731
- Testing
- Biocellulose Mask, Post Procedure Cream, Gentle Cleanser
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Healthy
A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20
This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20).
- Trial name
- NCT07792941
- Testing
- tilrekimig and rHuPH20
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.